Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile
Authors:
- Carlos Pérez-SánchezCPCarlos Pérez-Sánchez
- Patricia Ruiz-LimónPRPatricia Ruiz-Limón
- María Carmen Ábalos-AguileraMÁMaría Carmen Ábalos-Aguilera
- Yolanda Jiménez-GómezYJYolanda Jiménez-Gómez
- Lucía Fernández-Del RíoLucía Fernández-Del Río
- José Antonio González-ReyesJGJosé Antonio González-Reyes
- Eduardo Collantes-EstévezECEduardo Collantes-Estévez
- 1 October 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 37 (10) , 1923-1932
Abstract
Objective—: Antiphospholipid syndrome (APS) leukocytes exhibit an oxidative perturbation, directly linked to alterations in mitochondrial dynamics and metabolism. This disturbance is related to the patients’ prothrombotic status and can be prevented by in vitro treatment with coenzyme Q10. Our aim was to investigate short-term effects of in vivo ubiquinol (reduced coenzyme Q 10 [Q red ]) supplementation on markers related to inflammation and thrombosis in APS through a prospective, randomized, crossover, placebo-controlled trial. Approach and Results—: Thirty-six patients with APS were randomized to receive Q red (200 mg/d) or placebo for 1 month. Thirty-three patients with APS completed the intervention, which increased plasma coenzyme Q 10 . Q red improved endothelial function and decreased monocyte expression of prothrombotic and proinflammatory mediators, inhibited phosphorylation of thrombosis-related protein kinases, and decreased peroxides and percentage of monocytes with depolarized mitochondria; mitochondrial size was increased, and mitochondrial biogenesis–related genes were upregulated. Q red ameliorated extruded neutrophil extracellular traps in neutrophils and downregulated peroxides, intracellular elastase, and myeloperoxidase. Nanostring microRNA profiling revealed 20 microRNAs reduced in APS monocytes, and 16 of them, with a preponderance of cardiovascular disease–related target mRNAs, were upregulated. Monocytes gene profiling showed differential expression of 29 atherosclerosis-related genes, 23 of them changed by Q red . Interaction networks of genes and microRNAs were identified. Correlation studies demonstrated co-ordinated effects of Q red on thrombosis and endothelial function–associated molecules. Conclusions—: Our results highlight the potential of Q red to modulate the overexpression of inflammatory and thrombotic risk markers in APS. Because of the absence of clinically significant side effects and its potential therapeutic benefits, Q red might act as safe adjunct to standard therapies in APS. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02218476Keywords
This publication has 34 references indexed in Scilit:
- Immunotherapy in antiphospholipid syndromeInternational Immunopharmacology, 2015
- The Pathogenesis of the Antiphospholipid SyndromeNew England Journal of Medicine, 2013
- Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndromeAnnals of the Rheumatic Diseases, 2011
- Antiphospholipid syndromeThe Lancet, 2010
- Therapeutic use of coenzyme Q10and coenzyme Q10-related compounds and formulationsExpert Opinion on Investigational Drugs, 2010
- Patients with antiphospholipid syndrome display endothelial perturbationJournal of Autoimmunity, 2010
- Clinical aspects of coenzyme Q10: An updateNutrition, 2010
- High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndromeLupus, 2010
- Vascular Abnormalities, Paraoxonase Activity, and Dysfunctional HDL in Primary Antiphospholipid SyndromeJAMA, 2009
- Metabolism and function of coenzyme QBiochimica et Biophysica Acta (BBA) - Biomembranes, 2004